Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050596 · ClinicalTrials.gov registry record · Phase 2
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00050596 is a Phase 2 study that has completed, run by Bristol-Myers Squibb.
The verdict
NCT00050596, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single dose of cytotoxic chemotherapy (docetaxel) in combination with MDX-010
Interventions
- DRUG MDX-010 / MDX-010 + Docetaxel
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-11 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050596
The ClinicalTrials.gov registry entry for NCT00050596 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX-010 / MDX-010 + Docetaxel is the first listed.
NCT00050596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050596 about?
NCT00050596 is a clinical study titled "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer". The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single dose of cytotoxic chemotherapy (docetaxel) in combination with MDX-010
What is the current status of trial NCT00050596?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-11. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00050596?
The interventions under investigation include: MDX-010 / MDX-010 + Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00050596?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.